Sector News

Bristol-Myers says COO Caforio to take over as CEO

January 21, 2015
Life sciences
Bristol-Myers Squibb will soon have a new CEO. Chief Operating Officer Giovanni Caforio will take over the top exec job on May 5, when 64-year-old Lamberto Andreotti steps down from the role he has held for 5 years and takes over instead as executive chairman of the board.
 
“I also want to express my excitement that Giovanni has been appointed to succeed me as CEO,” Andreotti said in statement released by BMS late Tuesday. “I have a high level of confidence in Giovanni that is shared by everyone who has seen him consistently and successfully drive performance.”
 
Caforio is a 15-year veteran of the company who started at BMS as vice president and general manager in Italy. He is a medical doctor who got his MD from the University of Rome and started in the industry in medical affairs at Abbott Laboratories ($ABT). He has held a number of roles at BMS, including in its global oncology group, where he is said to have helped build its acknowledged leadership role in immuno-oncology.
 
That is the company’s beacon right now and the reason that JP Morgan analysts recently told investors they should be interested in BMS in 2015. They said that while the drugmaker’s shares have already escalated on the anticipated immuno-oncology sales from Yervoy and the newly FDA-approved Opdivo, they see “the potential for further upside to this figure (and BMY shares) from a number of important updates.”
 
It will be up to Caforio to make the most of this upside potential, but it was Andreotti who put the pieces into place. For his efforts he has been highly compensated, hitting $20.85 million in total compensation in 2013, making him the third best-paid biopharma CEO. There have been some stumbles with the successes. He was in charge for the acquisition of Amylin Pharmaceuticals to expand a diabetes partnership with AstraZeneca ($AZN), then promptly bailed out of that partnership in 2013. The company scrapped a few development programs as well, including early hepatitis C work and neuroscience.
 
By Eric Palmer
 

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.